-
AO 22-07
Regarding an arrangement whereby certain physicians have an ownership interest in a medical device company that manufactures products that may be ordered by the physician owners and a physician spouse of one of the physician owners.
-
AO 22-06
Regarding the provision of free genetic testing and genetic counseling services to individuals who meet specified clinical criteria.
-
AO 22-05
Regarding the proposed subsidization of certain Medicare cost-sharing obligations in the context of a clinical trial.
-
AO 22-04
Regarding a program through which Requestor provides certain individuals access to digital contingency management and related tools to treat substance use disorders, where the Program is funded by customers, which could include individuals’ health care providers or suppliers.
-
AO 22-03
Regarding Requestors’ proposal to pay salaries to, and nurse aide certification program tuition costs on behalf of, new employees who Requestors have hired to work as certified nurse aides for Requestors’ home health agencies.
-
AO 22-02
Regarding a proposed arrangement between Requestor and two individuals, pursuant to which Requestor and the individuals would reduce and subsidize certain costs incurred by qualifying patients of Requestor’s children’s hospital.
-
AO 22-01
Regarding the proposed expansion of discount programs for low-income individuals.
-
AO 21-20
Regarding Requestor’s proposal to create an online platform for: (i) users to search for and contact home-based health care providers, where providers listed on the website would be charged on a per-click basis; and (ii) advertising by individuals and entities other than home-based health care providers.
-
AO 21-19
Regarding Requestor’s provision of free eye drops that mitigate side effects for patients using one of its products.
-
AO 21-18
Regarding a proposed joint venture for the provision of therapy services.
-
AO 21-17
Regarding the proposed subsidization of beneficiary cost-sharing obligations for Medicare-covered services provided as part of a clinical trial.
-
AO 21-16
Regarding a pharmaceutical manufacturer’s arrangement to provide up to a specified number of trial units of a long-acting antipsychotic drug to certain hospitals for inpatient use.
-
AO 21-15
Regarding a pain management company’s proposal to retain net profits from services provided by an employed certified registered nurse anesthetist pursuant to a reassignment of billing rights.
-
AO 21-14
Regarding a proposal to extend an existing discount program for chiropractic patients to include Federal health care program beneficiaries.
-
AO 21-13
Regarding the proposed subsidization of beneficiary cost-sharing obligations for Medicare-covered services provided as part of a clinical trial.
-
AO 21-12
Regarding a critical access hospital’s proposal to offer an arrangement similar to a warranty to patients undergoing certain joint replacement procedures at the hospital.
-
AO 21-11
Regarding the use of a "preferred hospital" network as part of Medicare Supplemental Health Insurance ("Medigap") policies, whereby an insurance company contracts with a preferred hospital organization to provide discounts on the otherwise-applicable Medicare inpatient deductibles for its policyholders and, in turn, provides a premium credit of $100 off the next renewal premium to policyholders who use a network hospital for an inpatient stay.
-
AO 21-10
Regarding a dental provider’s provision of free routine and emergency dental services to certain indigent residents of skilled nursing facilities and nursing facilities.
-
AO 21-09
Regarding the use of a "preferred hospital" network as part of Medicare Supplemental Health Insurance ("Medigap") policies, whereby an insurance company would contract with a preferred hospital organization to provide discounts on the otherwise-applicable Medicare inpatient deductibles for its policyholders and, in turn, would provide a premium credit of $100 off the next renewal premium to policyholders who use a network hospital for an inpatient stay.
-
AO 21-08
Regarding financial assistance for transportation, lodging, and meals provided by a pharmaceutical manufacturer to certain patients potentially eligible for treatment with the pharmaceutical manufacturer’s drug.
Showing 41–60 of 447 advisory opinions
Sorted by most recent